Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.77 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.77 |
| ▸ | HTT | P42858 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.71 |
| ▸ | LMNA | P02545 | 2/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.68 |
| ▸ | TSHR | P16473 | 3/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.67 |
| ▸ | CNR1 | P21554 | 1/20 | 0.67 |
| ▸ | CNR2 | P34972 | 1/20 | 0.67 |
| ▸ | GAA | P10253 | 2/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | FLT3 | P36888 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3806687 | 0.95 | MAPT (0.77) | MAPTKDM4EHSD17B10HTTALDH1A1 | |
| SCHEMBL21603922 | 0.87 | KDM4E (1.00) | MAPTKDM4EHSD17B10ALDH1A1LMNA | |
| SCHEMBL4084306 | 0.87 | CNR1 (0.69) | MAPTKDM4EHSD17B10HTTALDH1A1 | |
| SCHEMBL11381277 | 0.86 | ALDH1A1 (0.80) | MAPTKDM4EHSD17B10ALDH1A1LMNA | |
| SCHEMBL8292134 | 0.86 | MAPT (0.73) | MAPTKDM4EHSD17B10HTTALDH1A1 | |
| SCHEMBL4390871 | 0.85 | MAPT (0.73) | MAPTKDM4EHSD17B10HTTALDH1A1 | |
| SCHEMBL21597480 | 0.85 | MAPT (0.60) | MAPTKDM4EHSD17B10HTTALDH1A1 | |
| SCHEMBL5450569 | 0.85 | KMT2A (0.69) | MAPTKDM4EHSD17B10HTTALDH1A1 | |
| SCHEMBL21597710 | 0.85 | KDM4E (0.69) | MAPTKDM4EHSD17B10HTTALDH1A1 | |
| SCHEMBL2306161 | 0.85 | MAPT (0.76) | MAPTKDM4EHSD17B10ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8802849-B2 | Tricyclic benzo[4,5]thieno-[2,3-d]pyrimidine-4-yl-amin derivatives, their salts, process for producing the compounds and their pharmaceutical use | VICHEM CHEMIE KUTATÓ KFT. (HU) | 2014-08-12 | — | — | US | disclosed |
| US-8802849-B2 | Tricyclic benzo[4,5]thieno-[2,3-d]pyrimidine-4-yl-amin derivatives, their salts, process for producing the compounds and their pharmaceutical use | VICHEM CHEMIE KUTATÓ KFT. (HU) | 2014-08-12 | — | — | US | disclosed |
| US-20110015214-A1 | TRICYCLIC BENZO[4,5]THIENO-[2,3-D]PYRIMIDINE-4-YL-AMIN DERIVATIVES, THEIR SALTS, PROCESS FOR PRODUCING THE COMPOUNDS AND THEIR PHARMACEUTICAL USE | VICHEM CHEMIE KUTATO KFT. (HU) | 2011-01-20 | — | — | US | disclosed |
| US-20110015214-A1 | TRICYCLIC BENZO[4,5]THIENO-[2,3-D]PYRIMIDINE-4-YL-AMIN DERIVATIVES, THEIR SALTS, PROCESS FOR PRODUCING THE COMPOUNDS AND THEIR PHARMACEUTICAL USE | VICHEM CHEMIE KUTATO KFT. (HU) | 2011-01-20 | — | — | US | disclosed |
| WO-2009104026-A1 | TRICYCLIC BENZO[4,5]THIENO-[2,3-D]PYRIMIDINE-4-YL-AMIN DERIVATIVES, THEIR SALTS, PROCESS FOR PRODUCING THE COMPOUNDS AND THEIR PHARMACEUTICAL USE | VICHEM CHEMIE KUTATÓ KFT (HU) | 2009-08-27 | — | — | WO | disclosed |
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | disclosed |
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | disclosed |
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | disclosed |
| EP-1670804-A2 | HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS | GPC Biotech AG (DE) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005023818-A2 | HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS | GPC BIOTECH AG (DE) | 2005-03-17 | — | — | WO | disclosed |
| WO-2005023818-A2 | HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS | GPC BIOTECH AG (DE) | 2005-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015214-A1 | TRICYCLIC BENZO[4,5]THIENO-[2,3-D]PYRIMIDINE-4-YL-AMIN DERIVATIVES, THEIR SALTS, PROCESS FOR PRODUCING THE COMPOUNDS AND THEIR PHARMACEUTICAL USE | TYMS, TYMP, DPYD | MAPT 3085/4885KDM4E 819/4885HSD17B10 2645/4885 |
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | TBCA, PARK7, NFATC1 | MAPT 21/4885KDM4E 3417/4885HSD17B10 635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.